Description
Zoladex (Goserelin) Capsules for Subcutaneous Use 3.6 mg
Ingredients
- Zoladex contains the active ingredient Goserelin acetate, a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH).
Dosage
- Zoladex 3.6 mg is administered as a single subcutaneous injection every 28 days using the provided syringe applicator.
Indications
- Zoladex is indicated for the palliative treatment of advanced prostate cancer, endometriosis, and uterine fibroids.
Contraindications
- Zoladex is contraindicated in individuals with known hypersensitivity to GnRH, pregnant or breastfeeding women, and pediatric patients.
Directions
- Before administration, ensure proper reconstitution of the medication according to the instructions provided.
- Administer the injection subcutaneously in the abdominal area, alternating sides with each dose.
Scientific Evidence
- Studies have shown that Zoladex (Goserelin) suppresses gonadotropin secretion, reducing testosterone levels in prostate cancer patients.
- Clinical trials have demonstrated efficacy in improving symptoms and quality of life in hormone-sensitive tumors.
Additional Information
- Regular monitoring of hormone levels is essential during treatment with Zoladex to ensure therapeutic effectiveness.
- Adverse effects may include hot flashes, fatigue, and decreased libido, which are typically transient and reversible.
Zoladex initially stimulates pituitary gonadotropins, leading to transient increases in sex hormone levels. Continuous use downregulates GnRH receptors, suppressing gonadotropin secretion and sex hormone production.
Zoladex offers a convenient and reversible option for androgen deprivation therapy in prostate cancer compared to surgical castration or anti-androgen therapy. Its subcutaneous formulation provides sustained drug release for consistent therapeutic levels.
